在表达 KIT 突变的黑色素瘤患者中观察到伊马替尼或索拉非尼的临床反应。
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
机构信息
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
出版信息
Br J Cancer. 2010 Apr 13;102(8):1219-23. doi: 10.1038/sj.bjc.6605635. Epub 2010 Apr 6.
BACKGROUND
Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation.
METHODS
A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17.
RESULTS
KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain.
CONCLUSION
The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status.
背景
KIT 突变在某些特定的黑色素瘤亚型中更为常见，而对 KIT 抑制的反应可能取决于所鉴定的突变。
方法
共对 32 例转移性肢端或黏膜黑色素瘤患者的 KIT 外显子 11、13 和 17 进行了突变筛查。
结果
黏膜黑色素瘤中 KIT 突变的发生率为 38%，肢端黑色素瘤为 6%。有 3 例患者接受了伊马替尼治疗，1 例接受了索拉非尼治疗。这 4 例患者均对治疗有反应，但其中 3 例随后在脑部进展。
结论
观察到的临床反应支持进一步研究根据 KIT 突变状态选择的 KIT 抑制剂在转移性黑色素瘤中的应用。
Zotero 插件